RenovoRx reported third-quarter 2026 revenue of $1.07 million, a nearly 300% increase from the prior year period and driven by expanded commercial adoption of its RenovoCath device. The company added five new active cancer center customers, bringing the total to 26, while maintaining full-year 2026 revenue guidance between $3.75 million and $4.25 million. Operating loss remained stable at approximately $3.2 million as selling expenses rose to support sales infrastructure growth. Cash reserves increased to $10.4 million following $3.5 million in proceeds from warrant exercises. The company is a life sciences firm commercializing targeted drug-delivery devices for oncology.
